# A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

> **NCT04466917** · PHASE3 · WITHDRAWN · sponsor: **Amgen**

## Conditions studied

- Metastatic Non-small Cell Lung Cancer (NSCLC)
- Non-squamous NSCLC

## Interventions

- **DRUG:** ABP 215
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04466917
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05-15
- **Primary completion:** 2022-11-13
- **Final completion:** 2022-11-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision to early terminate the study
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04466917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04466917, "A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04466917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*